Reset filter
Mots-clés
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
    1. 7.1. Anesthésie
    1. 7.2. Dermatologie
    1. 7.3. HNO
    1. 7.4. Gériatrie
    1. 7.5. Gynécologie/obstétrique
    1. 7.6. Médecine interne
      1. Hématologie
      1. Infectiologie
      1. Cardiologie/angiologie
      1. Pneumologie
      1. Gastroentérologie
      1. Néphrologie
      1. Endocrinologie/métabolisme
      1. Rhumatologie
    1. 7.7. Neurologie
    1. 7.8. Ophtalmologie
    1. 7.9. Médecine palliative
    1. 7.10. Pathologie/médécine légale
    1. 7.11. Pédiatrie
    1. 7.12. Psychiatrie/psychosomatique
    1. 7.13. Radiologie
    1. 7.14. Chirurgie
      1. Chirurgie générale/viscérale
      1. Neurochirurgie
      1. Chirurgie plastique
      1. Chirurgie cardiaque/thoracique
      1. Chirurgie traumatologique/orthopédie
      1. Chirurgie vasculaire
    1. 7.15. Urologie
    1. 7.16. Médecine dentaire/MKG
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

149 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Melanoma NCT00147550

- 19/10/2016 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00147550

Eligibility Melanoma NCT02475213

- 08/05/2019 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02475213

Eligibility Melanoma NCT02381314

- 07/05/2019 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02381314

Eligibility NCT00522834 Melanoma - Eligibility

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00522834

Eligibility Non-melanoma Skin Cancer NCT02409628

- 07/06/2016 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds; ODM derived from: https://clinicaltrials.gov/show/NCT02409628

Eligibility DRKS00003621 NCT00518895 Melanoma - Eligibility

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00518895

Eligibility NCT00395070 Metastatic Melanoma - Eligibility

- 15/04/2014 - 1 Formulaire, 2 Groupes Item, 11 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00395070

dbGaP phs000452 Melanoma Genome Sequencing Project - Eligibility

- 04/11/2022 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Levi Garraway, M.D. Ph. D, Dana Farber Cancer Institute, Boston, MA USA; Broad Institute, Cambridge, MA USA MeSH: Melanoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000452 Melanoma is the most prevalent cause of skin cancer morbidity and mortality. In order to characterize the full range of somatic mutations that may drive the growth of melanoma, we are sequencing tumor and normal DNA from a set of roughly 150 melanomas. For the majority of samples (approximately 90% of the cases) mutations in protein coding genes will be assessed in the exonic DNA of tumor-normal pairs using hybrid capture and paired-end DNA sequencing. Additionally, in a few DNA samples (approximately 10% of the cases) the entire genomes will be analyzed to assess the possible contribution of complex structural rearrangements contributing to oncogenesis. The sequencing data are supplemented by copy number profiling on the same tumors using high-density SNP arrays. Integration of these approaches will enable the unbiased and comprehensive characterization of both known and novel recurrent DNA alterations that arise in melanoma.

pht002589.v3.p1

1 Groupe Item 4 Eléments de données

pht002590.v3.p1

1 Groupe Item 5 Eléments de données

pht002591.v3.p1

1 Groupe Item 13 Eléments de données

pht002592.v3.p1

1 Groupe Item 8 Eléments de données

dbGaP phs001036 Genomic Characterization of Acral Melanoma - pht005268.v1.p1

- 05/08/2023 - 4 Formulaires, 1 Groupe Item, 2 Eléments de données, 1 Langue
Groupe Item: pht005268
Principal Investigator: Jeffrey Sosman, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Melanoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001036 In this study, we performed paired tumor/normal long insert whole genome and exome sequencing and tumor RNA sequencing on primary or metastatic acral melanoma tumors collected from 34 patients. Patients were enrolled from either Vanderbilt University or the Memorial Sloan-Kettering Cancer Center. We report an integrated analysis of DNA and RNA sequencing data to describe genomic and transcriptomic characteristics of acral melanoma.

pht005269.v1.p1

1 Groupe Item 3 Eléments de données

pht005270.v1.p1

1 Groupe Item 4 Eléments de données

pht005271.v1.p1

1 Groupe Item 7 Eléments de données

Basic Documentation, Medical History 1/2, Melanoma NCT00000000 - Basis Doku, Anamnese 1/2, Melanom NCT00000000

- 16/07/2016 - 1 Formulaire, 4 Groupes Item, 27 Eléments de données, 2 Langues
Groupes Item: Patient identification, Classification of Anamnesis, Consent, Anamnesis and risk factors Part A
Klinik und Poliklinik für Hautkrankheiten - Allgemeine Dermatologie und Venerologie - Direktor: Univ.-Prof. Dr. med. Th. A. Luger

Eligibility NCT00844064 Pancreatic Neoplasms, Melanoma, Colorectal Neoplasms - Eligibility

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 33 Eléments de données, 2 Langues
Groupes Item: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00844064

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Rheumatic Diseases; Systemic Lupus Erythematosus or Cutaneous Lupus; Sjogren's Syndrome (Report Final and Annex Report 2 Final)

- 02/11/2020 - 1 Formulaire, 25 Groupes Item, 95 Eléments de données, 1 Langue
Groupes Item: Administrative, Rheumatic Diseases, Rheumatic Diseases - Signs and Symptoms, Rheumatic diseases - Other signs and symptoms, Rheumatic diseases - Other signs and symptoms , Rheumatic diseases - Diagnostic Test Results, Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other diagnostic Procedure, Systemic Lupus Erythematosus or Cutaneous Lupus, Systemic Lupus Erythematosus or Cutaneous Lupus - Signs and symptoms (supporting the final diagnosis), Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms , Systemic Lupus Erythematosus or Cutaneous Lupus - Diagnostic Test Results, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other diagnostic Procedure , Sjogren's Syndrome, Sjogren's Syndrome - Signs and symptoms (supporting the final diagnosis), Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial